Feasibility of cetuximab given with a simplified schedule every 2 weeks in advanced colorectal cancer: A multicenter, retrospective analysis

Medical Oncology

Volumn 28, Issue SUPPL. 1, 2011, Pages

  Bouchahda, M ^a   MacArulla, T ^b   Liedo, G ^c   Levi F ^a   Elez, M E ^b   Paule, B ^a   Karaboue A ^a   Artru, P ^c   Tabernero, J ^b   MacHover, D ^a   Innominato, P ^a   Goldschmidt, E ^a   Bonnet, D ^d   Ducreux, M ^a   Castagne, V ^a   Guimbaud, R ^d  

^a HÔPITAL PAUL BROUSSE   (France)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c Clinique Saint Jean   (France)

^d TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

Cetuximab; Colorectal cancer; Every 2 weeks; Metastatic; Simplified schedule

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; UFT;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURGERY; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MONOTHERAPY; MUCOSA INFLAMMATION; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; RETROSPECTIVE STUDY; SKIN TOXICITY; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

EID: 84655164982     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-010-9716-8     Document Type: Article

References (16)

1. D Cunningham Y Humblet S Siena 2004 Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 391 392
2. HJ Lenz E Van Cutsem S Khambata-Ford 2006 Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines J Clin Oncol 24 4914 4921 (Pubitemid 46630920)
3. V Gebbia S Del Prete N Borsellino 2006 Efficacy and safety of cetuximab/irinotecan in chemotherapy-refractory metastatic colorectal adenocarcinomas: a clinical practice setting, multicenter experience Clin Colorectal Cancer 5 6 422 428
4. J Tabernero E Van Cutsem E Díaz-Rubio 2007 Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer J Clin Oncol 25 5225 5232 (Pubitemid 350232254)
5. JJ Lee E Chu 2007 First-line use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer Clin Colorectal Cancer 6 2 S42 S46
6. F Di Fiore 2007 Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy Br J Cancer 96 1166 1169 (Pubitemid 46625066)
7. W De Roock H Piessevaux J De Schutter 2008 KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab Ann Oncol 19 508 515 (Pubitemid 351325672)
8. Tabernero J, Cervantes A, Martinelli E, et al. Optimal dose of cetuximab (c) given every 2 weeks (q2w): a phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (q1wk) and q2w schedules in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol. 2006; 24 (Supl 18S):142s (Abstr 3085).
9. Pfeiffer P, Bjerregaard JK, Qvortrup C, et al. Simplification of cetuximab (Cet) administration: double dose every second week as a 60-min infusion.). J Clin Oncol 2007; 25 (Supl 18S):196s (Abstr 4133). Ann Oncol 2008; 19 (6):1141-1145.
10. Lévi F, Karaboué A, Gorden L, et al. Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability. Cancer Chemother Pharmacol. 2010; Epub ahead of print.
11. JY Douillard D Cunningham AD Roth 2000 Irinotecan combined with fluorouracil compared with fluorouracil alone: a multicenter randomised trial Lancet 355 1041 1047
12. A de Gramont A Figer M Seymour 2000 Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer J Clin Oncol 18 2938 2947 (Pubitemid 30644117)
13. C Tournigand T André E Achille 2004 FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study J Clin Oncol 22 229 237 (Pubitemid 41095086)
14. CS Fuchs J Marshall E Mitchell 2007 Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study J Clin Oncol 25 4779 4786 (Pubitemid 350086481)
15. A de Gramont M Buyse JC Abrahantes 2007 Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer J Clin Oncol 25 3224 3229 (Pubitemid 47325605)
16. M Scartozzi A Sobrero G Gasparini 2005 The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients Oncology 68 212 216 (Pubitemid 41158978)